A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1

Nature Chemical Biology

Volumn 12, Issue 3, 2016, Pages 180-187

  Stuckey, Jacob I ^a   Dickson, Bradley M ^a   Cheng, Nancy ^a   Liu, Yanli ^b   Norris, Jacqueline L ^a   Cholensky, Stephanie H ^a   Tempel, Wolfram ^b   Qin, Su ^b   Huber, Katherine G ^a   Sagum, Cari ^c   Black, Karynne ^c   Li, Fengling ^b   Huang, Xi Ping ^d   Roth, Bryan L ^d   Baughman, Brandi M ^a   Senisterra, Guillermo ^b   Pattenden, Samantha G ^a   Vedadi, Masoud ^b   Brown, Peter J ^b   Bedford, Mark T ^c   Min, Jinrong ^b   Arrowsmith, Cheryl H ^b   James, Lindsey I ^a   Frye, Stephen V ^a   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; PROTEIN INHIBITOR; UNC 3866; UNCLASSIFIED DRUG; CBX4 PROTEIN, HUMAN; CBX7 PROTEIN, HUMAN; LIGASE; OLIGOPEPTIDE; POLYCOMB GROUP PROTEIN; UBIQUITIN PROTEIN LIGASE; UNC3866;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CANCER GROWTH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHROMODOMAIN; GENE EXPRESSION REGULATION; HYDROGEN BOND; MALE; MEMBRANE PERMEABILITY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOSYNTHESIS; BIOTINYLATION; DRUG EFFECTS; ENZYME SPECIFICITY; GENETICS; HUMAN; ISOMERISM; METABOLISM; METHYLATION; MOLECULAR MODEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTINYLATION; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; GENE EXPRESSION REGULATION; HUMANS; ISOMERISM; LIGASES; MALE; METHYLATION; MICE; MODELS, MOLECULAR; OLIGOPEPTIDES; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB-GROUP PROTEINS; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES;

EID: 84955558290     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2007     Document Type: Article

References (60)

1. Wagner, T., Robaa, D., Sippl, W., Jung, M. Mind the methyl: methyllysine binding proteins in epigenetic regulation. Chem Med Chem 9, 466-483 (2014).
2. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
3. Kaustov, L. et al. Recognition and specificity determinants of the human cbx chromodomains. J. Biol. Chem. 286, 521-529 (2011).
4. Cao, Q. et al. The central role of EED in the orchestration of polycomb group complexes. Nat. Commun. 5, 3127 (2014).
5. Vandamme, J., Volkel, P., Rosnoblet, C., Le Faou, P., Angrand, P.O. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol. Cell Proteomics 10, M110.002642 (2011).
6. Morey, L., Aloia, L., Cozzuto, L., Benitah, S.A., Di Croce, L. RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells. Cell Reports 3, 60-69 (2013).
7. Jin, B. et al. Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. Cell Rep. 2, 1411-1424 (2012).
8. Eskeland, R. et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell 38, 452-464(2010).
9. Klauke, K. et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat. Cell Biol. 15, 353-362 (2013).
10. Bernard, D. et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 24, 5543-5551 (2005).
11. Forzati, F. et al. CBX7 is a tumor suppressor in mice and humans. J. Clin. Invest. 122, 612-623 (2012).
12. Shinjo, K. et al. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int. J. Cancer 135, 308-318 (2014).
13. Mansueto, G. et al. Identification of a new pathway for tumor progression: microRNA-181b up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer 1, 210-224 (2010).
14. Pallante, P. et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 68, 6770-6778 (2008).
15. Pallante, P. et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur. J. Cancer 46, 2304-2313 (2010).
16. Karamitopoulou, E. et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur. J. Cancer 46, 1438-1444 (2010).
17. Zhang, X.W. et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. J. Exp. Clin. Cancer Res. 29, 114 (2010).
18. Gil, J., Bernard, D., Martínez, D., Beach, D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat. Cell Biol. 6, 67-72 (2004).
19. Scott, C.L. et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc. Natl. Acad. Sci. USA 104, 5389-5394 (2007).
20. Tan, J. et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20, 563-575 (2011).
21. Wang, B. et al. Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma. Ann. Surg. Oncol. 20(suppl. 3): S684-S692 (2013).
22. Clermont, P.L. et al. Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. Br. J. Cancer111, 1663-1672 (2014).
23. Sauvageau, M., Sauvageau, G. Polycomb group genes: keeping stem cell activity in balance. PLoS Biol. 6, e113 (2008).
24. Konze, K.D. et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
25. Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014).
26. Hashizume, R. et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med. 20, 1394-1396 (2014).
27. Simhadri, C. et al. Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7). J. Med. Chem. 57, 2874-2883 (2014).
28. Ren, C. et al. Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain. Chem. Biol. 22, 161-168 (2015).
29. Frye, S.V. The art of the chemical probe. Nat. Chem. Biol. 6, 159-161 (2010).
30. Bunnage, M.E., Chekler, E.L., Jones, L.H. Target validation using chemical probes. Nat. Chem. Biol. 9, 195-199 (2013).
31. Workman, P., Collins, I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17, 561-577 (2010).
32. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
33. James, L.I. et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat. Chem. Biol. 9, 184-191 (2013).
34. Hopkinson, R.J. et al. Is JmjC oxygenase catalysis limited to demethylation Angew. Chem. Int. Edn. Engl. 52, 7709-7713 (2013).
35. Dickson, B.M. Approaching a parameter-free metadynamics. Phys. Rev. E 84, 037701 (2011).
36. Munõz, V., Thompson, P.A., Hofrichter, J., Eaton, W.A. Folding dynamics and mechanism of-hairpin formation. Nature 390, 196-199 (1997).
37. Xiao, Y., Chen, C., He, Y. Folding mechanism of-hairpin trpzip2: heterogeneity, transition state and folding pathways. Int. J. Mol. Sci. 10, 2838-2848 (2009).
38. Fischle, W., Franz, H., Jacobs, S.A., Allis, C.D., Khorasanizadeh, S. Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK(S/T) motifs. J. Biol. Chem. 283, 19626-19635 (2008).
39. Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215-220 (2012).
40. Kroeze, W.K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362-369 (2015).
41. Montgomery, N.D., Yee, D., Montgomery, S.A., Magnuson, T. Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation. J. Mol. Biol. 374, 1145-1157 (2007).
42. Kuzmichev, A., Jenuwein, T., Tempst, P., Reinberg, D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol. Cell 14, 183-193 (2004).
43. Ren, X., Vincenz, C., Kerppola, T.K. Changes in the distributions and dynamics of polycomb repressive complexes during embryonic stem cell differentiation. Mol. Cell. Biol. 28, 2884-2895 (2008).
44. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
45. Li, Q. et al. Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PLoS One 5, e13732 (2010).
46. Kong, Y., Cui, H., Ramkumar, C., Zhang, H. Regulation of senescence in cancer and aging. J. Aging Res. 2011, 963172 (2011).
47. Jarrard, D.F. et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosom. Cancer 19, 90-96 (1997).
48. Yaqinuddin, A., Qureshi, S.A., Qazi, R., Abbas, F. Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration. Cancer Cell Int. 8, 13 (2008).
49. Yaqinuddin, A., Qureshi, S.A., Qazi, R., Farooq, S., Abbas, F. DNMT1 silencing affects locus specific DNA methylation and increases prostate cancer derived PC3 cell invasiveness. J. Urol. 182, 756-761 (2009).
50. Mirochnik, Y. et al. Androgen receptor drives cellular senescence. PLoS One 7, e31052 (2012).
51. Hess, B., Kutzner, C., van der Spoel, D., Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435-447 (2008).
52. Tiwary, P., Parrinello, M. From metadynamics to dynamics. Phys. Rev. Lett. 111, 230602 (2013).
53. Voter, A.F. Hyperdynamics: accelerated molecular dynamics of infrequent events. Phys. Rev. Lett. 78, 3908-3911 (1997).
54. Bussi, G., Donadio, D., Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007).
55. Wigle, T.J. et al. Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J. Biomol. Screen. 15, 62-71 (2010).
56. Perfetti, M.T. et al. Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. ACS Chem. Biol. 10, 1072-1081 (2015).
57. Barsyte-Lovejoy, D. et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc. Natl. Acad. Sci. USA 111, 12853-12858 (2014).
58. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
59. Evans, P.R., Murshudov, G.N. How good are my data and what is the resolution Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
60. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).